| Name | Title | Contact Details |
|---|---|---|
Yuhong Qiu |
VP, Regulatory Affairs | Profile |
Jim Pepin |
General Counsel | Profile |
Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. At Insmed, we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed.
GenPrime is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Calysta, Inc. (www.calysta.com), Menlo Park, CA, is an innovator in industrial products for food and energy security. Calysta has two business units. Calysta Nutrition is developing and commercializing FeedKind™ protein, a natural, safe, non-GMO sustainable ingredient for fish feed and other applications. FeedKind™ protein is approved for sale in the European Union. Calysta Energy is developing high value industrial and chemical products with cost and performance advantages over current processes.
Predictive Biosciences is an innovative developer of molecular diagnostic tests for cancer diagnosis and monitoring. We are focused on understanding and meeting the needs of physicians by providing valuable diagnostic services and laboratory solutions.
MaxCyte is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines.